An exploration of how targeted nanoparticles and artificial intelligence algorithms combine to locate prostate cancer earlier ...

PanGIA Biotech, Inc. ("PanGIA Biotech" or "Company") announced that two research abstracts have been accepted for ...

Findings support model in which accelerated biological aging of mammary epithelia may underpin breast cancer susceptibility ...

“Our study highlights the growing potential of advanced biomarker science, combined with machine learning, to detect cancers ...

TOBY’s urine-based MCED test received FDA Breakthrough Device Designation. This is the first urine-based MCED platform ...

Prostate cancer remains one of the most common diseases among men, yet current screening methods often lead to unnecessary ...

Artificial intelligence (AI) could help physicians determine if survivors of childhood cancer need extra support - and the more information included in AI prompting, the better its performance. This ...

Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma Our study included a broad cohort of ...

TOBY, Inc., a biotechnology company developing non-invasive cancer screening technologies, today announced that the U.S. Food ...

New cfDNA test enables multicancer detection with high accuracy, offering a cost effective approach for early diagnosis and ...